0QZU Stock Overview
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QZU from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$404.77 |
52 Week High | US$446.29 |
52 Week Low | US$320.13 |
Beta | 0.37 |
1 Month Change | -1.04% |
3 Month Change | -4.25% |
1 Year Change | 17.89% |
3 Year Change | 90.04% |
5 Year Change | 142.50% |
Change since IPO | 266.27% |
Recent News & Updates
Recent updates
Shareholder Returns
0QZU | GB Biotechs | GB Market | |
---|---|---|---|
7D | 2.7% | 3.9% | 0.7% |
1Y | 17.9% | -26.7% | 3.0% |
Return vs Industry: 0QZU exceeded the UK Biotechs industry which returned -26.7% over the past year.
Return vs Market: 0QZU exceeded the UK Market which returned 3% over the past year.
Price Volatility
0QZU volatility | |
---|---|
0QZU Average Weekly Movement | 2.5% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QZU has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QZU's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
0QZU fundamental statistics | |
---|---|
Market cap | US$104.03b |
Earnings (TTM) | US$4.02b |
Revenue (TTM) | US$10.19b |
25.9x
P/E Ratio10.2x
P/S RatioIs 0QZU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QZU income statement (TTM) | |
---|---|
Revenue | US$10.19b |
Cost of Revenue | US$4.50b |
Gross Profit | US$5.68b |
Other Expenses | US$1.66b |
Earnings | US$4.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 15.55 |
Gross Margin | 55.81% |
Net Profit Margin | 39.46% |
Debt/Equity Ratio | 0% |
How did 0QZU perform over the long term?
See historical performance and comparison